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Abstract
Metastases in the bone marrow (BM) are grim prognostic factors in patients with neuroblastoma (NB). In spite of extensive
analysis of primary tumor cells from high- and low-risk NB patients, a characterization of freshly isolated BM-infiltrating
metastatic NB cells is still lacking. Our aim was to identify proteins specifically expressed by metastatic NB cells, that may be
relevant for prognostic and therapeutic purposes. Sixty-six Italian children over 18 months of age, diagnosed with stage 4
NB, were included in the study. Metastatic NB cells were freshly isolated from patients’ BM by positive immunomagnetic
bead manipulation using anti-GD2 monoclonal antibody. Gene expression profiles were compared with those obtained
from archived NB primary tumors from patients with 5y-follow-up. After validation by RT-qPCR, expression/secretion of the
proteins encoded by the up-regulated genes in the BM-infiltrating NB cells was evaluated by flow cytometry and ELISA.
Compared to primary tumor cells, BM-infiltrating NB cells down-modulated the expression of CX3CL1, AGT, ATP1A2 mRNAs,
whereas they up-regulated several genes commonly expressed by various lineages of BM resident cells. BM-infiltrating NB
cells expressed indeed the proteins encoded by the top-ranked genes, S100A8 and A9 (calprotectin), CD177 and CD3, and
secreted the CXCL7 chemokine. BM-infiltrating NB cells also expressed CD271 and HLA-G. We have identified proteins
specifically expressed by BM-infiltrating NB cells. Among them, calprotectin, a potent inflammatory protein, and HLA-G,
endowed with tolerogenic properties facilitating tumor escape from host immune response, may represent novel
biomarkers and/or targets for therapeutic intervention in high-risk NB patients.
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Introduction
Metastasis is the main cause of death in patients with
neuroblastoma (NB) [1–3]. In spite of aggressive multimodal
therapy, children over 18 months of age, presenting at diagnosis
with dissemination of malignant neuroblasts in the bone marrow
(BM), have a grim prognosis [1,2]. To achieve efficient target-
based therapies for high risk NB patients, characterization of the
genetic and biological features of metastatic cells is therefore
required.
In recent years, extensive characterization of primary tumor
cells from high-risk NB patients has been performed. DNA
abnormalities [4], gene expression profiles [5–7], and non-coding
RNAs expression [8,9] have been proposed as sensitive indicators of
NB tumor aggressiveness. Recently, a great effort has been
performed in order to validate the gene classifiers on independent
patient cohorts [7,10]. However, no information is presently
available on freshly isolated BM-infiltrating NB cells, with the
exception of few features [11,12]. After in vitro culture of BM
samples from patients with metastatic disease, Hansford et al. [13]
isolated cells endowed with high tumorigenic potential, suggesting
that metastatic cells maybe enriched intumor initiating cells(TICs).
Recently, a gene expression profiling of TICs has been reported
[14]. Culture conditions, however, may greatly change the
neoplastic cell features. Based on the above considerations, we
investigated the transcriptome of NB metastatic cells in comparison
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The proteins selectively overexpressed by the BM-infiltrating NB
cells may represent novel prognostic markers and potential targets
for biologically driven therapy for high risk NB patients.
Results
Characterization of BM-infiltrating GD2 positive cells
To ascertain whether genes expressed by the GD2 positive
fractions can be fully ascribed to the BM-infiltrating NB cells, six
freshly isolated GD2 positive cell populations were characterized
using different methodologies. As shown in Figure 1AB, FISH
analysis performed on GD2 positive cell preparations from two
patients with MYCN amplification showed presence of MYCN
amplification. Cytospins of GD2 positive cell preparations were
enriched in mononuclear NB cells expressing the NB-specific
markers GD2, CD56 [15] and NB84 [16] (Figure 1C, D and E,
respectively). Cytofluorimetric analysis showed that less than 5%
of the cells recovered by GD2-positive immunomagnetic bead
manipulation expressed CD45, whereas more than 95% expressed
the B7H3 antigen (Figure 1F and G, respectively). Previous studies
showed that B7H3 is not expressed by hematopoietic and stromal
BM cells [12,17]. Finally, all GD2 positive cell preparations
expressed the NB-specific molecular markers TH, GD2 synthase,
Phox2b, DCX, STX and ELAV-4 [18], at the same levels as primary
tumors, as assessed by RT-qPCR (Figure 2H). Taken together,
these results indicated that the GD2 positive fractions were
enriched in metastatic NB cells.
Gene expression profiling of BM-infiltrating NB cells
To identify genes specifically over- and under-expressed by BM-
infiltrating NB cells compared with primary tumor cells, eleven
freshly isolated GD2 positive preparations and twenty-one
archived NB primary tumors were analyzed by microarrays.
Eleven tumors were from alive patients and ten from patients who
died of the disease at 5-year follow-up (Figure 2). The genes
differently expressed in the three groups were identified by
applying the significance analysis of microarrays (SAM) by paired
comparisons with a false discovery rate (FDR)=1%. As shown in
Figure 3A–C, the samples from the three groups were placed on
different trunks of unsupervised hierarchical clustering dendro-
grams, which demonstrated that the selected sequences success-
fully classified the biological specimens.
The expression profile of the BM-infiltrating cells differed from
that of primary tumor cells from stage 4 patients dead at 5-year
follow-up in 970 probe sets (corresponding to 332 up-regulated
and 513 down-regulated unique transcripts), whereas 3158 probe
sets (corresponding to 1366 up-regulated and 1253 down-
regulated unique transcripts) were differently expressed compared
to primary tumor cells from stage 4 patients alive at 5-year follow-
up (Table S1). When compared to all twenty-one primary tumors
the BM-infiltrating GD2 positive cells differed in 3146 probe sets,
corresponding to 1435 down-regulated and 1224 up-regulated
unique transcripts (Table S1).
The genes down-modulated in BM-infiltrating cells compared
to primary tumor cells, irrespective of patient outcome, not
surprisingly were genes necessary to sustain an organized, tri-
dimensional structure, as that of a primary tumor, involving cell-
matrix signaling and adhesion, cell differentiation and blood vessel
development pathways (Table S2). The down-modulation of top-
ranked genes (namely, AGT, ATP1A2, BLK, CX3CL1, IGSF1,
IGFBP3, and TNC) was then tested by RT-qPCR in a subset of
samples hybridized to microarrays (5 samples from each group,
Figures S1, S2 and S3). CX3CL1, AGT, ATP1A2, and IGSF1
mRNAs proved to be significantly down-modulated in the BM-
infiltrating GD2 positive fractions compared to primary tumor
cells (P,0.0001, P=0.0325, P=0.0196, P=0.0047, respectively).
These results were further confirmed in an independent set of 15
additional samples (5 for each group, Figures S4, S5 and S6)
(P=0013, P=0.0012, P=0.0023, P=0.0314, respectively). It is
noteworthy that CX3CL1 (also called fractalkine) was down-
modulated irrespective of patient outcome, whereas AGT and
ATP1A2 were down-modulated only compared to primary tumor
cells from patients alive at 5-year follow-up (Figures S2, S3, S5,
S6), which suggests that they may represent novel surrogate
markers of tumor aggressiveness.
Among the genes significantly up-regulated in the BM-
infiltrating GD2 positive cells compared to primary tumor cells
(Table 1 and Table S2) several genes were commonly expressed by
various lineages of BM resident cells, namely: i) cathelicidine
(CAMP), myeloperoxidase (MPO), myeloid cell differentiation
antigen (MNDA), CD177, FC receptor, CD69 expressed by myelo-
monocytic cells; ii) mu chain, CD19, and BLK expressed by B cells
and iii) IL-1b, IL8, and CXCL7 (PPBP) expressed by several
hematopoietic and mesenchymal cells. To exclude that these
findings were due to the small amount of normal resident BM cells
present in our GD2 positive cell fractions, we directly checked
whether the BM-infiltrating NB cells expressed the proteins
encoded by these genes.
Expression and/or release of proteins encoded by
up-regulated genes in BM-infiltrating GD2 positive cells
The surface membrane expression of CD177, CD37, and
calprotectin, encoded by the S100A8 and S100A9 genes, was
assessed by cytofluorimetric analysis in ten fresh BM samples from
stage 4 patients with a median infiltration of 13% of GD2 positive
cells (range 2.5–33%), as assessed by anti-GD2 immunocytochem-
istry [19]. We also tested 3 membrane proteins expressed by NB
side population cells, namely: CD133, CD117 (c-kit) and CD271
(p75), and HLA-G, a monomorphic HLA class I molecule, whose
expression was not previously found in NB primary tumors [20].
As shown in Table 2, the BM-infiltrating GD2 positive cells co-
expressed CD177 and CD37 only in 3/9 and 3/6 BM samples,
respectively. Moreover, only 30% of the GD2 positive cells co-
expressed each of the two proteins (Table 2). Conversely, the BM-
infiltrating GD2 positive cells co-expressed HLA-G and the
S100A8/S100A9 complex (calprotectin) in 9/9 and 6/6 BM
samples, respectively. Most importantly, 100% of the GD2 positive
cells co-expressed both proteins (Table 2). With respect to NB side
population markers, 100% of GD2 positive cells in 4/4 BM
samples co-expressed p75, approximately 80% of GD2 positive
cells co-expressed c-kit in 4/10 samples, while none of 7 GD2
positive cell preparations co-expressed CD133 (Table 2).
Then we performed FACS analysis on three freshly-isolated
GD2 positive cell preparations to further confirm co-expression of
HLA-G and calprotectin by the BM-infiltrating NB cells. As
shown in Figure 4, the GD2 positive cells were CD45 negative,
expressed the B7H4 and CD56 NB-specific markers, and co-
expressed HLA-G and calprotectin, whereas c-kit, CD37 and
CD177 were co-expressed by a fraction of cells.
Next, we investigated whether freshly isolated BM-infiltrating
GD2 positive cells could release IL-1b, CXCL1, and CXCL7 in
the culture supernatant. Conditioned media from three prepara-
tions cultured for 48 hours were tested by ELISA. As reported in
Table 2, all three GD2 positive preparations released CXCL7
(mean=1.39 mg/mL), 1 out of 3 released CXCL1 (0.91 mg/mL)
and none released IL-1b.
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+ fractions from stage 4 NB patients. (A, B) FISH analysis of two GD2 positive cell
preparations from two patients with MYCN amplified tumors; (C, D, E) Cytospins of a GD2 positive cell preparation tested with anti-GD2 mAb
(different from the one used for immunomagnetic bead separation), anti-NB84 mAb, and anti-CD56 mAb, respectively; (F, G) cytofluorimetric analysis
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The aim of this study was to identify genes and proteins
differentially expressed by BM-infiltrating NB cells that could be
new potential therapeutic target and/or prognostic factors for high
risk NB patients. The results showed a significant down-regulation
of genesinvolved inextracellularmatrix-celladhesion pathways and
in blood vessel development. The genes more significantly down-
modulated were CX3CL1, AGT,a n dATP1A2. CX3CL1 (fractalk-
ine) is a neuronal chemokine capable of inducing immune effector
cell migration, adhesion and IFN-c secretion [21]. Intriguingly,
CX3CL1 down-modulation was observed in MYCN-amplified
primary NB tumors [22], supporting a role in limiting tumor
aggressiveness. AGT and ATP1A2 down-modulations were signifi-
cantly associated with patient outcome, which suggests that
expression of these proteins in primary tumors may have a
prognostic value. AGT encodes angiotensinogen, the precursor of
angiotensin, a key protein involved in blood vessel formation, and
ATP1A2is a sodium-potassiumATPase, implicated in ion-exchange
signaling. Further studies in larger cohorts of NB patients, however,
are needed to address their prognostic role.
In keeping with the specific aim of our study we focused instead
on the up-regulated genes. The BM-infiltrating GD2 positive cells
compared to primary tumor cells over-expressed several genes that
are normally expressed by different lineages of resident BM cells.
Our GD2 positive cell preparations were enriched in CD56+ and
NB84+ mononuclear NB cells, showed the same genetic
aberration as the primary tumor cells, and expressed NB-specific
genes, such as TH, GD2 synthase, Phox2b, ELAV4 and DCX, at the
same levels as primary tumor cells. However, they could not be
considered pure, therefore to avoid bias we evaluated the
expression of the proteins encoded by these genes in fresh BM
samples from stage 4 patients, together with proteins specifically
expressed by NB cells, by NB cell side population, and NB TICs.
Whereas in unprocessed BM samples from healthy individuals
GD2 expression is absent [23], in BM samples from stage 4 NB
patients GD2 positive cells represented about 20–30% of
mononuclear cells and 100% of these cells always co-express NB
Figure 2. Study design. Freshly isolated GD2 positive cells were obtained by positive immunomagnetic bead manipulation of BM aspirates, as
described in M&M section. Primary NB tumors were stored in the Tissue Repository at the Gaslini Institute.
doi:10.1371/journal.pone.0029922.g002
of a GD2 positive cell preparation stained with anti-CD45 mAb, and anti-B7H3 mAb, respectively. Horizontal bars indicated fluorescence threshold
obtained with irrelevant isotype-matched mAbs. Percentage of positive cells are indicated; H) RT-qPCR analysis of 6 GD2 positive cell preparations
(open circles) and 8 NB primary tumors (closed circles) tested for different NB-specific molecular markers. Horizontal bar indicates the median value of
each set.
doi:10.1371/journal.pone.0029922.g001
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the GD2-positive BM-infiltrating cells were indeed metastatic NB
cells. Surface expression of CD133 never occurred whereas
expression of CD177 and CD37, two clusters of hematopoietic
differentiation, was occasionally detected in fractions of BM-
infiltrating GD2 positive cells, in a way similar to CD117 (c-kit).
Expression of CD37, a member of the tetraspanin family, has been
involved in metastasis [24], while nothing is known about the
possible role in cancer of CD177, a glycosyl-phosphatidylinositol
(GPI)-linked surface protein, normally secreted by neutrophils
[25]. Thus, our findings suggest that the role, if any, of CD133,
CD117, CD37 and CD177 can not be pivotal in determining the
aggressiveness of the metastatic cells. Similarly, CXCL1 secretion
was not consistent, even if CXCL1 was shown to accelerate tumor
growth, angiogenesis, and stromal recruitment during the
metastatic process in melanoma, breast and colon cancer [26].
Conversely, the BM-infiltrating GD2 positive cells released the
chemokine CXCL7, encoded by the PPBP gene. CXCL7 was
found over-expressed in breast cancer patients [27], and CXCL7-
transfected breast cancer cells were more invasive than parental
cells [28]. More interestingly, all freshly isolated GD2 positive cells
co-expressed not only CD56 and B7H3 proteins [29,30], but also
calprotectin and HLA-G. The heterodimeric protein calprotectin,
a product of the S100A8 and S100A9 genes, is a member of
the S100 protein family, composed of small (10–12 kDa) acidic
calcium and zinc binding proteins. Calprotectin is normally
expressed by phagocytes and polymorphonuclear leukocytes. The
S100A8/A9 complex is located in the cytosol and, upon elevation
of intracellular calcium levels, is translocated to the cytoskeleton
and then to the plasma membrane. Lacking a trans-membrane
signaling domain, calprotectin remains attached by non-covalent
association and, during inflammation, the S100A8/A9 complex is
released into biological fluids. Calprotectin may induce apoptosis
of different cell types, through zinc sequestration, and it has been
widely used as biomarker of inflammation [31]. Moreover,
calprotectin has been identified as a potent ligand of the Toll-
like receptor 4 (TLR4) [32], which is responsible for specific
response to endogenous danger signals. Since we recently
demonstrated [33] that resident BM cells from patients with NB
up-regulated the expression of genes involved in inflammation and
response to biotic stimuli, it is tempting to speculate that
calprotectin may be one of the signals involved.
In spite of its properties as enhancer of innate immune
responses, calprotectin was found selectively expressed by invasive
breast [34] and thyroid [35] cancer cells. Recently, its expression
was associated with cancer progression and metastasis in different
Figure 3. Gene expression profiling. Hierarchically clustered heat maps of differentially expressed probe sets in BM-infiltrating metastatic GD2
positive cells (GD2+) and (A) primary tumors from patients who died of stage 4 NB (NB_dead), (B) primary tumors from patients with stage 4 NB alive
at 5 year follow-up (NB_RC), (C) primary tumors from patients with stage 4 NB, irrespective of outcome (NB). Each color patch represents the
expression level of genes (row) in that sample (column), with a continuum of expression levels from bright green (lowest) to bright red (highest).
Non-detected signals are indicated in white.
doi:10.1371/journal.pone.0029922.g003
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PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e29922Table 1. Top-ranked genes differentially expressed by BM-infiltrating metastatic GD2 positive cells (GD2+) and primary tumor cells
from patients with stage 4 NB, dead and alive at 5-year follow-up, selected by SAM analyses.
GeneName Description tumors stage 4 alive GD2+ Diff. Mean
S100A9 Homo sapiens S100 calcium binding protein A9 (calgranulin B) (S100A9), mRNA
[NM_002965]
5.66 12.89 27.23
S100A8 Homo sapiens S100 calcium binding protein A8 (calgranulin A) (S100A8), mRNA
[NM_002964]
8.55 15.09 26.55
CAMP Homo sapiens cathelicidin antimicrobial peptide (CAMP), mRNA [NM_004345] 5.3 11.52 26.21
MPO Homo sapiens myeloperoxidase (MPO), nuclear gene encoding mitochondrial
protein, mRNA [NM_000250]
5.21 10.75 25.54
MNDA Homo sapiens myeloid cell nuclear differentiation antigen (MNDA), mRNA
[NM_002432]
7.37 11.86 24.49
CD177 full-length cDNA clone CS0DI015YO17 of Placenta Cot 25-normalized of
Homo sapiens (human). [CR592446]
4.63 8.94 24.31
LYZ Homo sapiens lysozyme (renal amyloidosis) (LYZ), mRNA [NM_000239] 7.63 11.82 24.19
FCAR Homo sapiens Fc fragment of IgA, receptor for (FCAR), transcript variant 1,
mRNA [NM_002000]
4.08 7.95 23.87
LILRA2 Homo sapiens leukocyte immunoglobulin-like receptor, subfamily A (with TM
domain), member 2 (LILRA2), mRNA [NM_006866]
4.4 8.1 23.7
PPBP Homo sapiens pro-platelet basic protein (chemokine (C-X-C motif) ligand
7) (PPBP), mRNA [NM_002704]
5.28 8.88 23.59
HSH2D Homo sapiens hematopoietic SH2 domain containing (HSH2D),
mRNA [NM_032855]
6.53 9.96 23.43
IL1B Homo sapiens interleukin 1, beta (IL1B), mRNA [NM_000576] 7.13 10.55 23.42
NFE2 Homo sapiens nuclear factor (erythroid-derived 2), 45kDa (NFE2), mRNA [NM_006163] 7.08 10.45 23.37
TREM1 Homo sapiens triggering receptor expressed on myeloid cells 1 (TREM1),
mRNA [NM_018643]
4.39 7.71 23.32
IL18RAP Homo sapiens interleukin 18 receptor accessory protein (IL18RAP), mRNA
[NM_003853]
6.68 9.92 23.24
NCF1 Homo sapiens neutrophil cytosolic factor 1, (chronic granulomatous disease,
autosomal 1) (NCF1), transcript variant 1, mRNA [NM_000265]
7.54 10.78 23.24
BLK Homo sapiens B lymphoid tyrosine kinase (BLK), mRNA [NM_001715] 5.53 8.74 23.21
P2RY2 Homo sapiens purinergic receptor P2Y, G-protein coupled, 2 (P2RY2), transcript
variant 1, mRNA [NM_176072]
5.43 8.58 23.15
CD19 Homo sapiens CD19 molecule (CD19), mRNA [NM_001770] 7.62 10.64 23.02
FCRL5 Homo sapiens Fc receptor-like 5 (FCRL5), mRNA [NM_031281] 5.58 8.59 23
GeneName Description tumors stage 4 dead GD2+ Diff. Mean
RNASE2 Homo sapiens ribonuclease, RNase A family, 2 (liver, eosinophil-derived
neurotoxin) (RNASE2), mRNA [NM_002934]
3.64 10.89 27.25
S100A9 Homo sapiens S100 calcium binding protein A9 (S100A9), mRNA [NM_002965] 6.06 12.98 26.92
S100A8 Homo sapiens S100 calcium binding protein A8 (S100A8), mRNA [NM_002964] 8.53 15.03 26.51
S100P Homo sapiens S100 calcium binding protein P (S100P), mRNA [NM_005980] 6.39 12.44 26.05
MPO Homo sapiens myeloperoxidase (MPO), nuclear gene encoding mitochondrial
protein, mRNA [NM_000250]
4.77 10.68 25.91
CAMP Homo sapiens cathelicidin antimicrobial peptide (CAMP), mRNA [NM_004345] 5.75 11.38 25.63
CD177 Homo sapiens CD177 molecule (CD177), mRNA [NM_020406] 3.87 9.17 25.3
MNDA Homo sapiens myeloid cell nuclear differentiation antigen (MNDA), mRNA
[NM_002432]
7.1 12.16 25.06
AQP9 Homo sapiens aquaporin 9 (AQP9), mRNA [NM_020980] 5.65 10.63 24.98
RETN Homo sapiens resistin (RETN), mRNA [NM_020415] 4.95 9.83 24.88
LYZ Homo sapiens lysozyme (renal amyloidosis) (LYZ), mRNA [NM_000239] 7.28 11.88 24.6
LILRA3 Homo sapiens leukocyte immunoglobulin-like receptor, subfamily
A (without TM domain), member 3 (LILRA3), mRNA [NM_006865]
5.03 9.48 24.45
BLK Homo sapiens B lymphoid tyrosine kinase (BLK), mRNA [NM_001715] 4.38 8.75 24.37
FCAR Homo sapiens Fc fragment of IgA, receptor for (FCAR), transcript variant 1,
mRNA [NM_002000]
3.72 8.07 24.35
CD19 Homo sapiens CD19 molecule (CD19), mRNA [NM_001770] 6.38 10.61 24.23
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molecule [36]. Hiratsuka et al. [37] demonstrated that the
calprotectin-TLR4 axis guides metastatic cell invasion, and
facilitates the survival and proliferation of cancer cells at the
metastatic site. Thus, calprotectin expressed by BM-infiltrating
metastatic NB cells may contribute to their survival and
proliferation in the BM.
The BM-infiltrating GD2 positive cells also expressed HLA-G, a
monomorphic HLA class Ib molecule, over-expressed in a wide
variety of human cancers, endowed with tolerogenic properties
facilitating tumor escape from host immune response [38]. Since
primary NB tumors did not express HLA-G [20], it is conceivable
that HLA-G may contribute to the high aggressiveness of BM-
infiltrating NB cells throughout its immunosuppressive activity.
Therefore, the search for drugs able to suppress HLA-G
expression might increase the efficacy of immunotherapeutic
intervention in high risk patients.
Further studies will be necessary to understand whether the
expression of calprotectin and HLA-G by BM-infiltrating NB cells is
transcriptionally regulated[39] ora c q u i r e db ym e c h a ni s m ssu c ha sc e ll
fusion [40] or microvesicles [41]. Nonetheless, our study demonstrated
that BM-infiltrating NB cells express genes not found in the primary
tumor cells of patients with stage 4 disease, which may be responsible
in part for their dismal prognosis. Since BM microenvironment in
patients with localized and metastatic NB was similar despite their
completely different outcomes [33], the identification of proteins
specifically expressed by BM-infiltrating metastatic cells represents the
only effective tool to find novel therapeutic targets and novel
prognostic markers for high risk NB patients. In this view, calprotectin
and HLA-G may deserve future studies.
Materials and Methods
Study design
Sixty-six Italian children over 18 months of age, diagnosed with
stage 4 NB according to INSS criteria [42] were included in the
study. Diagnosis and staging were made at the referral center
participating in the Italian Cooperative Group for Neuroblastoma.
Central review of primary tumor histology was performed at the
Gaslini Institute. Diagnostic work-up included evaluation of the
primary tumor by appropriate imaging, morphological examina-
tion of two BM aspirates and at least one bone trephine biopsy,
catecholamine metabolite assay in urine, ferritin and lactate
dehydrogenase assays in serum, and evaluation of MYCN
oncogene status in the primary tumor. Demographic, clinical
and follow-up data were retrieved from the Italian Neuroblastoma
Registry [43].
The study was approved by the Ethics Committees of each
Italian Cooperative Group for Neuroblastoma center (http://
www.aieop.org/?q=mappa centri.html). All patients’ guardians
signed a written consent allowing the use of samples and clinical
data for research purposes. The procedures were in accordance
with ethical standards and the Helsinki Declaration.
GeneName Description tumors stage 4 dead GD2+ Diff. Mean
IL1B Homo sapiens interleukin 1, beta (IL1B), mRNA [NM_000576] 6.48 10.68 24.2
CD37 Homo sapiens CD37 molecule (CD37), transcript variant 1, mRNA [NM_001774] 6.46 10.37 23.91
SIGLEC5 Homo sapiens sialic acid binding Ig-like lectin 5 (SIGLEC5), mRNA [NM_003830] 6.05 9.9 23.84
VNN2 Homo sapiens vanin 2 (VNN2), transcript variant 1, mRNA [NM_004665] 7.06 10.83 23.77
CXCL1 Homo sapiens chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating
activity, alpha) (CXCL1), mRNA [NM_001511]
6.78 10.52 23.74
NCF1 Homo sapiens neutrophil cytosolic factor 1, (chronic granulomatous disease,
autosomal 1) (NCF1), mRNA [NM_000265]
7.11 10.8 23.69
FCRL5 Homo sapiens Fc receptor-like 5 (FCRL5), mRNA [NM_031281] 4.87 8.55 23.68
LILRA5 Homo sapiens leukocyte immunoglobulin-like receptor, subfamily A (with TM
domain), member 5 (LILRA5), transcript variant 2, mRNA [NM_181985]
4.64 8.32 23.68
P2RY2 Homo sapiens purinergic receptor P2Y, G-protein coupled, 2 (P2RY2), transcript
variant 1, mRNA [NM_176072]
5.17 8.81 23.64
CD69 Homo sapiens CD69 molecule (CD69), mRNA [NM_001781] 7.29 10.9 23.62
IL8RB Homo sapiens interleukin 8 receptor, beta (IL8RB), mRNA [NM_001557] 4.11 7.51 23.4
doi:10.1371/journal.pone.0029922.t001
Table 1. Cont.
Table 2. Surface expression and identification of released
proteins encoded by genes up-regulated in BM-infiltrating
GD2 positive preparations, as assessed by cytofluorimetric
analysis
a and ELISA
b.
Protein
Number of
samples
Positive
(N) %
Mean of
co-expression
c
CD177
a 9 3 33 30.5
CD37
a 6 3 50 29.0
HLA-G
a 9 9 100 100
Calprotectin
a 6 6 100 100
CD271 (p75)
a,d 4 4 100 100
CD117 (c-kit)
a,e 10 4 34 77.7
CD133
a,f 70 0 0
CXCL7
b 33 1 0 0
CXCL1
b 31 3 3
IL-1b
b 30 0
cpercentage of double positive cells.
dBassili et al, Cancer Chemother Pharmacol 2010; 65:1047–56.
eHirschmann-Jax et al, Proc Natl Acad Sci U S A 2004;101:14228–33.
fKomuro et al, J Pediatr Surg 2007;42: 2040–45, Tong et al, World J Pediatr
2008;4:58–62.
doi:10.1371/journal.pone.0029922.t002
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freshly isolated GD2 positive BM-infiltrating NB cells collected at
diagnosis were included in the study. All tumors were classified as
Schwannian stroma poor NBs according to the International
Neuroblastoma Pathology Committee [44]. They contained at
least 80% of neuroblastoma cells, as assessed by the pathologist
(CG). Three tumors showed MYCN amplification, one in the first
group and two in the second group. The use of primary tumors
stored in the Gaslini tumor repository ‘‘Biobanca integrata tessuto-
genomica’’ was approved by the Gaslini’s Ethics Committee.
Immunomagnetic separation of BM-infiltrating NB cells
To isolate BM-infiltrating NB cells, fresh BM samples from
patients with stage 4 disease older than 18 months at diagnosis,
containing 10–30% of NB cells, as assessed by immunocytochem-
ical analyses [19] were subjected to immunomagnetic bead
manipulation, as described in details in Scaruffi et al. [33]. The
GD2 positive fraction, containing less than 5% of CD45+
hematopoietic cells as assessed by flow cytometry, was centrifuged
and the cell pellet subjected to further analyses (Figure 1). The
amount of recovered GD2 positive cells was around 10
6/mL of
BM sample.
Cytofluorimetric analysis
For characterization of GD2 positive cell preparations (Figure 1),
surface membrane staining was done using the anti-B7H3 (5B14,
kindly provided by Prof. A. Moretta) [30] and the anti-CD45
(Becton Dickinson, San Jose, CA) monoclonal antibodies (mAbs).
To evaluate surface protein expression by GD2 positive cells,
whole BM samples from ten stage 4 NB patients and three freshly
isolated BM-infiltrating GD2
+ cells were stained with the following
mAbs: anti-GD2 (purified from the G2a hybridoma cell line [45]),
anti-B7H3 (5B14), anti-p75 (Novus Biologicals, Littleton, CO),
anti-HLA-G PE (Exbio, Prague, CZ), anti-calprotectin FITC
(BMA Biomedicals, Augst, Switzerland), anti-CD177 FITC
(Becton Dickinson), anti-CD37 FITC (Becton Dickinson), anti-
CD133 APC (Miltenyi Biotech, Bergisch Gladbach, Germany),
anti-CD117 PE (Miltenyi Biotech), anti-CD45 FITC (Becton
Dickinson) and anti-CD56 PC7 (Beckman Coulter, Brea, CA).
Irrelevant isotype-matched mAbs, used at the same concentration
as the test mAbs, were used as negative control. One610
4 events
were acquired using a Gallios Cytometer (Beckman Coulter) and
data were analyzed with the Kaluza software (Beckman Coulter).
The percentage of positive cells was calculated using a threshold
line based on the maximum fluorescence intensity obtained with
the irrelevant isotype-matched mAb.
Immunocytochemistry of GD2 positive cell preparations
Immunocytochemical labeling was performed according to
standardized procedures for BM samples [46]. Briefly, cytospins of
freshly isolated GD2 positive cells were fixed in 4% buffered para-
formaldehyde for 10 minutes. After washing with PBS, cytospins
were incubated for 30 minutes with proper dilutions of unlabeled
anti-GD2 (Becton Dickinson), anti-NB84 and anti-CD56 (both
from Dako, Golstrup, Denmark) in 1% PBS/BSA (Gibco, Paisley,
UK). After washing in PBS, cytospins were incubated for
30 minutes with an unlabeled secondary antibody (Dako) diluted
in 1% PBS/BSA. After washing, staining was obtained by
incubation with APAAP complex (Dako) and Fuchsin+Substrate
Chromogene System (Dako). Cytospins were counterstained with
Figure 4. Flow cytometric analysis of BM samples. A representative cytofluorometric analysis of a freshly isolated GD2 positive cell preparation,
tested with anti-B7H3 (5B14) and anti-GD2 mAb in combination with: anti-CD45, anti-HLA-G, anti-calprotectin, anti-CD56, anti-CD117 (c-kit), anti-
CD37 and anti-CD177. The first plot shows anti-B7H3 specific mAb fluorescence intensity (Y axis) versus side-scatter (X axis), whereas all the other
plots show specific mAb fluorescence intensity (Y axes) versus anti-GD2 specific mAb fluorescence intensity (X axes). Letters indicated in each panel
are assigned from Kaluza software to each different single sample analysis.
++ indicates double positive cells (upper right panel),
+2 and
2+ indicate
single positive cells (upper left and lower right panels),
22 indicates double negative cells (lower left panel). Percentages of single positive (first plot)
or double positive (all the other plots) cells are indicated.
doi:10.1371/journal.pone.0029922.g004
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medium (Dako). As negative controls, slides were incubated with
mouse normal serum (X0910, Dako) and processed as above.
FISH analysis
Double colour FISH was performed on interphase nuclei of
GD2 positive cell preparations using the ON MYCN(2p24)/
LAF(2q11) probe (Kreatech, Amsterdam, The Nederlands).
Cytospins were pretreated with RNase and pepsin. Probes were
handled according to the manufacturer’s protocol: slide and
probe combinations were incubated simultaneously on a hot
plate at 80uC for 5 min. Overnight incubation at 37uC, washes
and DAPI nuclei counterstaining were done according to
standard protocol. For each tumor at least 200 nuclei were
surveyed. The terminology used was in accordance with the
guidelines of the European Neuroblastoma Quality Assessment
(ENQUA) group [47].
Extraction of total RNA
Total RNA was extracted from the GD2 positive cell
preparations using the RNeasy Micro kit (Qiagen, Helden,
Germany), according to the manufacturer’s procedure that
includes an RNase-free DNAse I digestion to eliminate contam-
inating DNA. From primary NB tumors total RNA was extracted
as previously described [9]. Quantification and quality control of
total RNA were performed by RNA 6000 NanoH and PicoH assays
on a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).
Only samples with RNA integrity number $6.0 were included in
the study.
Gene expression profiling
Five-hundred ng of total RNA were hybridized to Human GE
4x44K v2 Microarray Kit (Agilent Technologies) containing
probes for 41,000 human transcripts following the One-color
microarray-based gene expression analysis protocol (www.agilent.
com), as described in detail in Scaruffi et al. [33]. All data is
MIAME compliant and that the raw data has been deposited in
National Center for Biotechnology Information Gene Expression
Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and are
accessible through GEO accession number GSE 25623a.
Gene Ontology analysis
DAVID software was used to determine biological pathways
significantly over-represented in our datasets.
Reverse transcription and quantitative real-time PCR (RT-
qPCR)
RNA (1 mg) was reverse transcribed using random primers and
120 U Superscript III (MMLV) reverse-transcriptase in a total
volume of 20 mL (Invitrogen Life Technologies, Carlsbad, CA).
cDNA was diluted 10-fold in molecular biology grade water to a
final concentration of 5 ng/mL assuming 100% reverse transcrip-
tion efficiency.
For GD2 positive cell characterization (Figure 1), level of
expression of TH, beta-1,4-N-acetyl-galactosaminyl transferase 1 (GD2-
synthase), DCX, ELAV-4, Phox2b and STX was evaluated according
to standardized conditions [48], using 8 primary NB tumors as
positive controls.
For validation of microarray results (Figure 1), we first assessed
ATP5B as the best reference gene for both GD2-positive and
primary tumor cells by means of geNorm
TM Housekeeping Gene
Selection Kit and software (v. 3.4) (PrimerDesign Ltd, UK). Then,
the expression of AGT, ATP1A2, BLK, CX3CL1, IGFBP3, IGSF2
and TNC genes was quantified by pre-optimized FAM-labeled
TaqManH Gene Expression assays (Applied Biosystem, Foster
City, CA). Negative controls (water as template and RNA reverse-
transcribed without MMLV) and a positive control (cDNA from
the IMR-32 NB cell line [48] were always included. To determine
the expression of each target gene relative to ATP5B, the equation
2
2DCq, where DCq=(Cqtarget gene2Cqb2M), was calculated.
A checklist prepared according to the Minimum Information for
Publication of Quantitative Real-Time PCR Experiments (MIQE)
is submitted as Supplementary Data.
Secretion of cytokines
Secretion of CXCL1, CXCL7, and IL-1b was assessed by using
DuoSet ELISA Development System (R&D Systems, Minneapolis,
MN), following manufacturer’s protocol. Briefly, supernatants
from three freshly separated GD2 positive cell preparations were
collected after 48-hour culture in DMEM containing 20% FBS.
H2SO4 5 M (100 mL/well) was added to stop the reaction and
optical densities were measured at 450 nm using Infinite M200
reader (Tecan, Ma ¨nnedorf, Switzerland). The assay’s lowest
threshold was 7.8 ng/mL for all analytes. Each sample was tested
in duplicate.
Statistical analysis
Statistical analyses of gene expression profiling and of RT-
qPCR data were performed as detailed in Scaruffi et al. (in press
PBC). All significance tests were two tailed and a P value,0.05
was considered as statistically significant.
Supporting Information
Table S1 Transcripts differentially expressed between BM-
infiltrating GD2 positive cells and primary tumors from i) patients
dead of stage 4 NB, ii) patients with stage 4 NB alive at 5 year
follow-up, and iii) patients with stage 4 NB, irrespective of
outcome, selected by SAM analysis.
(PDF)
Table S2 The most significantly (P#0.05) enriched Gene
Ontology Biological Process (GOBP) terms in gene signatures of
BM-infiltrating GD2 positive cells and primary NB tumors from
stage 4 patients.
(XLS)
Figure S1 Box-and-Whisker plots of AGT, ATP1A2, BLK,
CX3CL1, IGSF1, IGFBP3, and TNC gene expression values by
qPCR (normalized to ATP5B, and after logarithmic transforma-
tion of original measures) in 5 GD2 positive cells (GD2+) and 5
primary tumors (NB) previously hybridized to microarray. Each
box represents the values from the 25
th to 75
th percentile, the
middle line represents the median, and a line extends from the
minimum to the maximum value, excluding outliers which are
displayed as blue dots.
(TIF)
Figure S2 Box-and-Whisker plots of AGT, ATP1A2, BLK,
CX3CL1, IGSF1, IGFBP3, and TNC gene expression values by
qPCR (normalized to ATP5B, and after logarithmic transforma-
tion of original measures) in 5 GD2 positive cells (GD2+) and 5
primary tumors from patients dead of disease (NB_dead),
previously hybridized to microarrays. Each box represents the
values from the 25
th to 75
th percentile, the middle line represents
the median, and a line extends from the minimum to the
maximum value.
(TIF)
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CX3CL1, IGSF1, IGFBP3, and TNC gene expression values by
qPCR (normalized to ATP5B, and after logarithmic transforma-
tion of original measures) in 5 GD2 positive cells (GD2+) and 5
primary tumors from alive patients (NB_alive), previously
hybridized to microarrays. Each box represents the values from
the 25
th to 75
th percentile, the middle line represents the median,
and a line extends from the minimum to the maximum value,
excluding outliers which are displayed as blue dots.
(TIF)
Figure S4 Box-and-Whisker plots of AGT, ATP1A2, CX3CL1,
and IGSF1 gene expression values by qPCR (normalized to
ATP5B, and after logarithmic transformation of original measures)
in 5 GD2 positive cells (GD2+) and 5 primary tumors from stage 4
patients (NB) (independent sample set). Each box represents the
values from the 25
th to 75
th percentile, the middle line represents
the median, and a line extends from the minimum to the
maximum value, excluding outliers which are displayed as blue
dots.
(TIF)
Figure S5 Box-and-Whisker plots of AGT, ATP1A2, CX3CL1,
and IGSF1 gene expression values by qPCR (normalized to
ATP5B, and after logarithmic transformation of original measures)
in 5 GD2 positive cells (GD2+) and 5 primary tumors from stage 4
patients dead of disease (NB_dead) (independent sample set). Each
box represents the values from the 25
th to 75
th percentile, the
middle line represents the median, and a line extends from the
minimum to the maximum value, excluding outliers which are
displayed as blue dots.
(TIF)
Figure S6 Box-and-Whisker plots of AGT, ATP1A2, CX3CL1,
and IGSF1 gene expression values by qPCR (normalized to
ATP5B, and after logarithmic transformation of original measures)
in 5 GD2 positive cells (GD2+) and 5 primary tumors from alive
stage 4 patients (NB_alive) (independent sample set). Each box
represents the values from the 25
th to 75
th percentile, the middle
line represents the median, and a line extends from the minimum
to the maximum value, excluding outliers which are displayed as
blue dots.
(TIF)
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